間葉系幹細胞市場：タイプ別、適応症別、分離源別、用途別 - 2024年～2030年の世界予測

間葉系幹細胞市場規模は2023年に35億1,000万米ドルと推計され、2024年には39億8,000万米ドルに達し、CAGR 13.63％で2030年には85億9,000万米ドルに達すると予測されています。

間葉系幹細胞（MSCs）は、骨芽細胞、軟骨細胞、筋細胞、脂肪細胞など様々な細胞型に分化できる多能性間質細胞です。これらの細胞は、特定の条件下で培養するとプラスチック表面に接着する能力と、特定の表面マーカーの発現によって識別されます。MSCは、骨髄、脂肪組織、臍帯血、歯髄など様々な組織から採取されます。MSCの使用拡大を促す主な要因としては、その再生可能性、免疫調節特性、変形性関節症、心血管疾患、移植片対宿主病などの様々な疾患の治療における使用が挙げられます。さらに、新たな再生医療への応用や遺伝子治療のデリバリー・ビークルとしての可能性も、研究や産業界の関心をさらに高めています。しかし、MSCの使用には免疫拒絶反応のリスクや悪性化の可能性があります。これらの問題に対処するためには、MSCの単離と培養技術の標準化が重要であり、またin vitroでの増殖と品質管理のための強固なプロトコルの開発が必要です。組織工学の進歩と3Dバイオプリンティング技術の開発により、MSCを用いた複雑な組織や臓器の構築が可能になるかもしれないです。さらに、個別化医療が重視されるようになったことで、より的を絞った効果的なMSCを用いた治療が行われるようになると思われます。

タイプ免疫学的安全性と個別化された性質を持つ自家MSCは、長期的な治療に有益です。

同種MSCはドナーに由来するもので、様々なレシピエントに使用するために拡大・保存されます。これらの細胞は、急性期医療の場面で重要な、拡張性と即時利用可能性において優位性があります。同種MSCは、患者が早急な介入を必要とし、自身の細胞を提供する時間や能力がないような場合に、しばしば適応となります。加えて、健康が損なわれている患者や特定の遺伝的疾患を持つ患者は、潜在的に不健康な細胞を使用するリスクを避けるために、同種MSCからより多くの利益を得ることができます。自家MSCは患者自身の体から採取されるため、免疫拒絶反応の可能性が低く、ドナー調達に関連する倫理的配慮を避けることができます。自己MSCは、慢性疾患や、変性疾患などの治療が計画されている場合に好まれます。このような個別化により、適合性が確保され、免疫反応のリスクが低くなります。

適応症CVD治療のためのMSCに関する実質的な研究開発活動

骨や軟骨の修復におけるMSCの必要性は、変形性関節症、関節リウマチ、骨粗鬆症の有病率の増加や、骨折の治癒改善の必要性によって高まっています。MSCは、骨芽細胞や軟骨細胞に分化する可能性があり、それによって損傷した骨や軟骨組織を修復するための再生選択肢を提供するという点で、極めて重要です。MSCは、特に腫瘍部位へのホーミング能力と抗がん剤送達の可能性から、がん治療のための新しい治療アプローチとなります。心血管疾患（CVD）は世界の死因のトップであり、MSCは損傷した心臓組織を再生する可能性があるとして注目されています。心臓組織の再生能力は限られているため、この応用の必要性は切迫しています。移植片対宿主病（GvHD）は、造血幹細胞移植の重篤な合併症です。MSCには免疫調節作用があり、GvHDの治療に適しています。MSCの免疫調節作用は、多発性硬化症、ループス、クローン病などの自己免疫疾患や炎症性疾患の治療薬となる可能性があります。これらの疾患は慢性的であり、既存の治療法では不十分であるため、新しい治療法の必要性が高いです。肝硬変や肝炎などの肝疾患は肝不全に至る可能性があり、肝移植が唯一の決定的な治療法です。MSC療法は、肝臓の再生と線維症の修復を促進することで、より侵襲性の低い代替療法を提供できる可能性があります。

分離源：骨髄由来MSCの高い細胞収量と確立された治療用途

脂肪組織由来MSC（AD-MSCs）は、脂肪吸引の際に脂肪組織から採取されることが多いです。AD-MSCsは豊富で採取が容易であり、組織1gあたりMSCsの収量が高いです。AD-MSCsは強い分化能を示し、再生医療や美容への応用に理想的です。骨髄由来MSC（BM-MSC）は、その分化能の高さから、最も広範に研究されているMSCのひとつです。骨髄由来MSCは、血液疾患の治療や骨・軟骨の修復に用いられることが多いです。臍帯血由来MSCは、出産後の臍帯血から採取されます。臍帯血由来MSCは、他の由来MSCに比べ成熟度が低く、免疫調節機能に影響を及ぼす可能性があります。卵管から分離された間葉系幹細胞は、胚に類似した性質を持つため、再生医療における将来が期待される新規の供給源です。胎児肝由来のMSCは、その高い増殖率と様々なタイプの細胞を生成する可能性から同定されています。その利用は主に研究が中心で、特に肝疾患と肝再生に関心があります。肺由来MSCは、その部位特異的な利点から、呼吸器疾患の研究や治療に有用です。末梢血から採取される間葉系幹細胞は、侵襲性の低いプロセスで採取できるという利点があります。末梢血由来MSCは、骨髄や脂肪組織由来MSCに代わる非侵襲的な方法であるが、末梢血に含まれるMSCの濃度は、はるかに低いため、単離が難しく、臨床応用が制限される可能性があります。

応用ヒトの疾患を模倣し、薬剤の有効性を試験する能力による、疾患モデリングと創薬におけるMSCの利点

MSCは、様々な疾患の病態生理学を理解するための疾患モデリングにおいて、ますます活用されるようになってきています。研究者たちは、MSCが複数の細胞型に分化する能力を持ち、免疫調節特性を持つことから、MSCを優先的に利用しています。MSCは、医薬品開発や創薬の初期段階において重要な役割を担っています。その分化能により、研究者はMSC由来の様々な細胞型に対する新薬の効果を観察することができます。これは、新しい治療法を発見し、薬剤のメカニズムを理解するために不可欠です。幹細胞バンキングは、MSCの重要な用途として浮上してきており、民間および公的なバンクが、将来の治療用途のために保管サービスを提供しています。組織工学は、損傷した組織を修復したり置き換えたりするための生物学的代替物の開発にMSCが不可欠である成長分野です。MSCはまた、化学物質や薬剤の安全性を評価するためのin vitro毒性試験にも用いられています。MSCの多能性は、複数の細胞種における毒性予測に特に適しています。

地域別の洞察

南北アメリカ、特に米国とカナダでは、間葉系幹細胞（MSCs）の研究と治療開発に携わるバイオテクノロジー企業が存在感を示しており、多額の投資と細胞治療製品に対する有利な規制の流れに支えられています。これらの国々では、幹細胞治療に対するFDAの先進的な姿勢と先進的なヘルスケア・インフラに後押しされ、変形性関節症、創傷治癒、移植片対宿主病などの用途を中心に、MSCを用いた臨床試験が盛んに行われています。中国、日本、韓国などに代表されるAPAC地域は、再生医療を科学的進歩のための重要な分野として政府が積極的に推進しており、MSCへの関心がダイナミックかつ急速に高まっています。APACの企業は、MSCの研究と臨床応用の両方を強化するために、製造能力の拡大や国際的な協力関係の確立に多額の投資を行っています。EMEA地域は混在したシナリオを示しており、欧州諸国は南北アメリカと同様の厳しい規制基準を遵守しています。欧州医薬品庁（EMA）は、MSC製品の安全性と有効性を保証する包括的な規制枠組みを提供しています。とはいえ、欧州には幹細胞研究に特化した先駆的な企業や研究機関がいくつかあり、品質と製造管理及び品質管理基準（GMP）の遵守に重点を置いています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは間葉系幹細胞市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、間葉系幹細胞市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.間葉系幹細胞市場の市場規模および予測は？

2.間葉系幹細胞市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.間葉系幹細胞市場の技術動向と規制枠組みは？

4.間葉系幹細胞市場における主要ベンダーの市場シェアは？

5.間葉系幹細胞市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 間葉系幹細胞調査の成長
    • 高齢者人口の増加と慢性疾患の増加
    • 幹細胞治療の継続的な情勢
  • 抑制要因
    • 幹細胞療法の標準化と規制の欠如
  • 機会
    • 間葉系幹細胞の新たな応用
    • 間葉系幹細胞製品のコラボレーションとパートナーシップの拡大と治療革新の推進
  • 課題
    • ヒトMSC療法に関連する倫理的および安全性の問題
• 市場セグメンテーション分析
  • タイプ：自己MSCの免疫学的安全性と個別化により、長期治療に有益となる
  • 適応症：CVD治療のためのMSCに関する実質的な研究開発活動
  • 分離源：骨髄由来MSCの高い細胞収量と確立された治療用途
  • 応用：ヒトの疾患を模倣し、薬剤の有効性を試験する能力があるため、疾患モデル化と創薬におけるMSCの利点
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 間葉系幹細胞市場：タイプ別

• 同種異系
• 自家移植

第7章 間葉系幹細胞市場：適応症別

• 骨と軟骨の修復
• がん
• 循環器疾患
• 移植片対宿主障害
• 炎症性および免疫性疾患
• 肝臓疾患

第8章 間葉系幹細胞市場：分離源別

• 脂肪組織
• 骨髄
• 臍帯血
• 卵管
• 胎児肝臓
• 肺
• 末梢血

第9章 間葉系幹細胞市場：用途別

• 疾患モデル
• 医薬品開発と発見
• 幹細胞バンキング
• ヒト組織工学
• 毒性学研究

第10章 南北アメリカの間葉系幹細胞市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の間葉系幹細胞市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの間葉系幹細胞市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Cellcolabs、調査およびGMPグレードのMSCおよびMSC誘導体に関するREPROCELLとの提携を発表
  • PromoCell、GMP準拠の間葉系幹細胞の分離と増殖のためのPromoExQ MSC成長培地XFを発売
  • PluristyxとStemmattersがiPSC由来MSCバンクの開発と製造で提携を発表

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. MESENCHYMAL STEM CELLS MARKET RESEARCH PROCESS
• FIGURE 2. MESENCHYMAL STEM CELLS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. MESENCHYMAL STEM CELLS MARKET DYNAMICS
• FIGURE 7. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. MESENCHYMAL STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. MESENCHYMAL STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MESENCHYMAL STEM CELLS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY BONE & CARTILAGE REPAIR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY BONE & CARTILAGE REPAIR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY GVHD, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY GVHD, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INFLAMMATORY & IMMUNOLOGICAL DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY INFLAMMATORY & IMMUNOLOGICAL DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY LIVER DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY LIVER DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY ADIPOSE TISSUES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY ADIPOSE TISSUES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CORD BLOOD, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY CORD BLOOD, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY FALLOPIAN TUBE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY FALLOPIAN TUBE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY FETAL LIVER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY FETAL LIVER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY LUNG, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY LUNG, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY DRUG DEVELOPMENT & DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY DRUG DEVELOPMENT & DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY STEM CELL BANKING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY STEM CELL BANKING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL MESENCHYMAL STEM CELLS MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 56. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 57. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 58. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 65. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 66. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 67. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 68. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 69. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 70. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 71. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 72. ARGENTINA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 73. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 74. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 75. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 76. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 77. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 78. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 79. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 80. BRAZIL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 81. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 82. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 83. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 84. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 85. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 86. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 87. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. CANADA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 90. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 91. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 92. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 93. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 94. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 95. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 96. MEXICO MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 97. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 98. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 99. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 100. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 101. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 102. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 103. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 106. UNITED STATES MESENCHYMAL STEM CELLS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 108. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 110. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 112. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 114. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 116. ASIA-PACIFIC MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 117. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 118. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 119. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 120. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 121. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 122. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 123. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. AUSTRALIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 126. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 127. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 128. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 129. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 130. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 131. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 132. CHINA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 133. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 134. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 135. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 136. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 137. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 138. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 139. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. INDIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 142. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 143. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 144. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 145. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 146. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 147. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 148. INDONESIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 149. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 150. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 151. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 152. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 153. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 154. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 155. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 156. JAPAN MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 157. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 158. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 159. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 160. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 161. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 162. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 163. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. MALAYSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 166. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 167. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 168. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 169. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 170. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 171. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. PHILIPPINES MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 174. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 175. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 176. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 177. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 178. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 179. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 180. SINGAPORE MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 181. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 182. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 184. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 186. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 188. SOUTH KOREA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 189. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 190. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 191. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 192. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 193. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 194. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 195. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. TAIWAN MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 198. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 199. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 200. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 201. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 202. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 203. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 204. THAILAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 205. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 206. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 207. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 208. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 209. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 210. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 211. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 212. VIETNAM MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 223. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 224. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 225. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 226. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 227. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 228. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 229. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 230. DENMARK MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 231. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 232. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 233. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 234. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 235. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 236. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 237. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 238. EGYPT MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 239. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 240. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 241. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 242. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 243. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 244. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 245. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 246. FINLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 247. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 248. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 249. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 250. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 251. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 252. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 253. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 254. FRANCE MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 255. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 256. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 257. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 258. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 259. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 260. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 261. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 262. GERMANY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 263. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 264. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 265. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 266. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 267. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 268. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 269. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 270. ISRAEL MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 271. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 272. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 273. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 274. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 275. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 276. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 277. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 278. ITALY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 279. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 280. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 281. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 282. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 283. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 284. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 285. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 286. NETHERLANDS MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 287. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 288. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 289. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 290. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 291. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 292. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 293. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 294. NIGERIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 295. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 296. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 297. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 298. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 299. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 300. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 301. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 302. NORWAY MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 303. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 304. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 305. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 306. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 307. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 308. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 309. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 310. POLAND MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 311. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 312. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 313. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 314. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 315. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 316. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 317. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 318. QATAR MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 319. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 320. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 321. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 322. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 323. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 324. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 325. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 326. RUSSIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 327. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 328. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 329. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 330. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 331. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2018-2023 (USD MILLION)
• TABLE 332. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY SOURCE OF ISOLATION, 2024-2030 (USD MILLION)
• TABLE 333. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 334. SAUDI ARABIA MESENCHYMAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 335. SOUTH AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 336. SOUTH AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 337. SOUTH AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 338. SOUTH AFRICA MESENCHYMAL STEM CELLS MARKET SIZE, BY INDICATIO

[189 Pages Report] The Mesenchymal Stem Cells Market size was estimated at USD 3.51 billion in 2023 and expected to reach USD 3.98 billion in 2024, at a CAGR 13.63% to reach USD 8.59 billion by 2030.

Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. These cells are identified by their ability to adhere to plastic surfaces when cultured under specific conditions and by the expression of certain surface markers. MSCs are harvested from various tissues, including bone marrow, adipose tissue, umbilical cord blood, and dental pulp. The major factors driving the expansion of their use include their regenerative potential, immunomodulatory properties, and their use in treating various diseases, such as osteoarthritis, cardiovascular disease, and graft-versus-host disease. Additionally, their potential in emerging regenerative medicine applications and as delivery vehicles for gene therapy has further catalyzed research and industry interest. However, there is a risk of immune rejection and potential for malignant transformation with the use of MSCs. To address these issues, standardization of MSC isolation and culture techniques is critical, as well as the development of robust protocols for in vitro expansion and quality control. Advances in tissue engineering and the development of 3D bioprinting technologies may allow for the construction of complex tissues and organs using MSCs. Additionally, the growing emphasis on personalized medicine is likely to lead to more targeted and effective MSC-based therapies.

Type: Immunological safety and personalized nature of autologous MSCs to make them beneficial for long-term treatments

Allogeneic MSCs are derived from a donor, which are then expanded and stored for use in different recipients. These cells have an advantage in scalability and immediate availability, which is critical in acute care scenarios. Allogeneic MSCs are often indicated in cases where patients require immediate intervention and may not have the time or ability to donate their own cells. In addition, individuals with compromised health or certain genetic disorders may benefit more from allogeneic MSCs to avoid the risks of using their potentially unhealthy cells. Autologous MSCs are harvested from the patient's own body, which diminishes the likelihood of immune rejection and avoids the ethical considerations associated with donor sourcing. Autologous MSCs are preferred in chronic conditions or when treatments are planned, such as for degenerative diseases. This personalization ensures compatibility and a lower risk of immune response.

Indication: Substantial research and development activities on MSCs for the treatment of CVDs

The need for mesenchymal stem cells (MSCs) in bone and cartilage repair is driven by the increasing prevalence of osteoarthritis, rheumatoid arthritis, and osteoporosis, as well as the necessity for improved healing of bone fractures. MSCs are pivotal for their potential to differentiate into osteoblasts and chondrocytes, thereby providing a regenerative option for repairing damaged bone and cartilaginous tissues. MSCs represent a novel therapeutic approach for cancer treatment, particularly due to their homing capabilities to tumor sites and their potential to deliver anti-cancer agents. Cardiovascular diseases (CVD) are a leading cause of death globally, and MSCs have gained attention for their potential to regenerate damaged heart tissue. The need for this application is pressing due to the limited regenerative capacity of the cardiac tissue. Graft-versus-host disease (GvHD) is a severe complication of hematopoietic stem cell transplantation. MSCs have immunomodulatory properties that make them a suitable treatment for managing GvHD. MSCs' immunomodulatory effects serve as a potential therapy for autoimmune and inflammatory diseases such as multiple sclerosis, lupus, and Crohn's disease. These conditions have a high need for new therapies due to their chronic nature and the inadequacy of existing treatments. Liver diseases, such as cirrhosis and hepatitis, can lead to liver failure, for which liver transplantation is the only definitive treatment. MSC therapies could offer a less invasive alternative by promoting liver regeneration and fibrosis repair.

Source of Isolation: High cell yield and established therapeutic use of bone-marrow derived MSC

Adipose tissue-derived MSCs (AD-MSCs) are obtained from fat tissues, often during liposuction procedures. They are abundant and easy to harvest, with a high yield of MSCs per gram of tissue. AD-MSCs exhibit a strong capacity for differentiation, making them ideal for regenerative medicine and cosmetic applications. Bone marrow-derived MSCs (BM-MSCs) are one of the most extensively studied MSC types due to their high differentiation potential. They are often used in treating hematological diseases and repairing bone and cartilage. Cord blood-derived MSCs are collected from the umbilical cord blood after childbirth, a non-invasive and ethically uncontroversial source. They are less mature than MSCs from other sources, which may have implications for their immunomodulatory functions. Mesenchymal stem cells isolated from the fallopian tube are a novel source with a promising future in regenerative medicine due to their embryonic-like properties. Fetal liver-derived MSCs have been identified for their high proliferation rate and potential to generate a variety of cell types. Their use is primarily research-focused, with particular interest in liver diseases and hepatic regeneration. Lung-derived MSCs are valuable for studying and treating respiratory diseases due to their site-specific advantages. Mesenchymal stem cells obtained from peripheral blood have the advantage of being harvested through a less invasive process. They offer a non-invasive alternative to bone marrow and adipose tissue sources, but the MSCs found in peripheral blood are in far lower concentrations, which can complicate isolation and limit their clinical applications.

Application: Benefits of MSCs in disease modeling and drug discovery due to their ability to mimic human diseases and test drug efficacy

MSCs are increasingly being utilized in disease modeling to understand the pathophysiology of various disorders. Researchers prioritize MSCs for their ability to differentiate into multiple cell types and for their immunomodulatory properties. MSCs play a crucial role in the early phases of drug development and discovery. Their differentiation capabilities enable researchers to observe the effects of new drugs on various cell types derived from MSCs. This is essential for discovering new therapies and understanding drug mechanisms. Stem cell banking has emerged as an important application for MSCs, with private and public banks offering storage services for future therapeutic use. Tissue engineering is a growing field where MSCs are essential for the development of biological substitutes to repair or replace damaged tissues. MSCs are also used for in vitro toxicology studies to evaluate the safety of chemicals and drugs. MSCs' multipotency makes them particularly suited for predicting toxicity in multiple cell types.

Regional Insights

In the Americas, particularly the United States and Canada, there is a robust presence of biotechnology firms engaged in mesenchymal stem cell (MSCs) research and therapy development, supported by significant investment and favorable regulatory pathways for cell therapy products. These countries are major in clinical trials involving MSCs, focusing on applications such as osteoarthritis, wound healing, and graft-versus-host disease, propelled by the FDA's progressive stance on stem cell therapies and advanced healthcare infrastructure. The APAC region, led by countries such as China, Japan, and South Korea, showcases a dynamic and rapidly growing interest in MSCs, with governments actively promoting regenerative medicine as a key area for scientific advancement. APAC companies are investing heavily in scaling up manufacturing capabilities and in establishing international collaborations to enhance both research and clinical application of MSCs. The EMEA region presents a mixed scenario, with European countries adhering to stringent regulatory standards similar to those in the Americas. The European Medicines Agency (EMA) offers a comprehensive regulatory framework that ensures the safety and efficacy of MSC products. Nonetheless, Europe is home to several pioneering companies and research institutions dedicated to stem cell research, with a focus on quality and adherence to Good Manufacturing Practice (GMP) standards.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Mesenchymal Stem Cells Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Mesenchymal Stem Cells Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Mesenchymal Stem Cells Market, highlighting leading vendors and their innovative profiles. These include AMS Biotechnology, Astellas Pharma Inc., Athersys, Inc., Axol Biosciences Ltd., BrainStorm Cell Therapeutics Inc., Cell Applications, Inc., Celprogen, Inc., Cyagen Biosciences, Inc., Cytori Therapeutics Inc., Genlantis, Inc., Globus Medical, Hope Biosciences, LLC, Lonza Group AG, Merck KGaA, Mesoblast Limited, Neuromics, Pluri Biotech Ltd., PromoCell GmbH, R&D Systems, Inc., ScienCell Research Laboratories, Inc., Smith & Nephew PLC, Stemcell Technologies Inc., Stemedica Cell Technologies, Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Mesenchymal Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Allogeneic
  • Autologous

• Indication
  • Bone & Cartilage Repair
  • Cancer
  • Cardiovascular Disease
  • GvHD
  • Inflammatory & Immunological Disease
  • Liver Diseases

• Source of Isolation
  • Adipose Tissues
  • Bone Marrow
  • Cord Blood
  • Fallopian Tube
  • Fetal Liver
  • Lung
  • Peripheral Blood

• Application
  • Disease Modeling
  • Drug Development & Discovery
  • Stem Cell Banking
  • Tissue Engineering
  • Toxicology Studies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Mesenchymal Stem Cells Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Mesenchymal Stem Cells Market?

3. What are the technology trends and regulatory frameworks in the Mesenchymal Stem Cells Market?

4. What is the market share of the leading vendors in the Mesenchymal Stem Cells Market?

5. Which modes and strategic moves are suitable for entering the Mesenchymal Stem Cells Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growth in Mesenchymal Stem Cell-Based Research
    • 5.1.1.2. Rising Geriatric Population Coupled with Growth in Chronic Diseases
    • 5.1.1.3. Continuously Evolving Landscape of Stem Cell Therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of Standardized and Regulated Delivery of Stem Cell Therapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging Applications of Mesenchymal Stem Cells
    • 5.1.3.2. Growing Collaborations and Partnerships and Advancing Therapeutic Innovations of Mesenchymal Stem Cell Products
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical & Safety Issues Associated with Human MSC Therapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Immunological safety and personalized nature of autologous MSCs to make them beneficial for long-term treatments
  • 5.2.2. Indication: Substantial research and development activities on MSCs for the treatment of CVDs
  • 5.2.3. Source of Isolation: High cell yield and established therapeutic use of bone-marrow derived MSC
  • 5.2.4. Application: Benefits of MSCs in disease modeling and drug discovery due to their ability to mimic human diseases and test drug efficacy
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Mesenchymal Stem Cells Market, by Type

• 6.1. Introduction
• 6.2. Allogeneic
• 6.3. Autologous

7. Mesenchymal Stem Cells Market, by Indication

• 7.1. Introduction
• 7.2. Bone & Cartilage Repair
• 7.3. Cancer
• 7.4. Cardiovascular Disease
• 7.5. GvHD
• 7.6. Inflammatory & Immunological Disease
• 7.7. Liver Diseases

8. Mesenchymal Stem Cells Market, by Source of Isolation

• 8.1. Introduction
• 8.2. Adipose Tissues
• 8.3. Bone Marrow
• 8.4. Cord Blood
• 8.5. Fallopian Tube
• 8.6. Fetal Liver
• 8.7. Lung
• 8.8. Peripheral Blood

9. Mesenchymal Stem Cells Market, by Application

• 9.1. Introduction
• 9.2. Disease Modeling
• 9.3. Drug Development & Discovery
• 9.4. Stem Cell Banking
• 9.5. Tissue Engineering
• 9.6. Toxicology Studies

10. Americas Mesenchymal Stem Cells Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Mesenchymal Stem Cells Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Mesenchymal Stem Cells Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Cellcolabs Announces Partnership With REPROCELL for Research And GMP Grade MSC And MSC Derivatives
  • 13.3.2. PromoCell Launches PromoExQ MSC Growth Medium XF for GMP-Compliant Isolation and Expansion of Mesenchymal Stem Cells
  • 13.3.3. Pluristyx and Stemmatters Announce Partnership to Develop and Manufacture iPSC-derived MSC Banks

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio